Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Viking Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned across 2 distinct examiners and 2 distinct art units, so the available record shows separate examination channels rather than concentration in one technical group.
WHITE, DAWANNA SHAR-DAY is the busiest examiner, with 1 pending matter. Because the examiner and art-unit assignments are distributed, counsel should preserve matter-specific analysis of the cited references and claim scope. A coordinated portfolio position may still help maintain consistent biotechnology terminology, but the distinct assignments call for separate response strategies and docket review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836713 | POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUND | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836719 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | AGGARWAL, SAHIL CHANDER | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18836713 | POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUND | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Non-Final OA | — | Pending | Aug 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialViking Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sahil Chander Aggarwal has the most, with 1 of Viking Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
